New weight problems medicine are virtually twice as efficient as most at the moment accepted weight reduction medicine
According to a new landmark study conducted by Northwestern Medicine and other institutions, a new anti-obesity drug has been shown to be nearly twice as effective at losing weight as some of the weight loss drugs currently on the market.
The drug semaglutide, taken in an amount of 2.4 mg once a week, suppresses the appetite centers in the brain to reduce hunger and calorie intake. It could be a game changer for those struggling with obesity, which affects more than 40% of adults in the United States. Obesity is linked to several complications such as type 2 diabetes, high blood pressure, heart disease, arthritis, sleep apnea, some cancers, and decreased life expectancy.
The study was published online February 10 in the New England Journal of Medicine.
“This is by far the most effective intervention we’ve seen for weight management when compared to many of the drugs currently in existence,” said author Dr. Robert Kushner, professor of medicine and medical education at Northwestern University’s Feinberg School of Medicine and an internist with Northwestern Medicine. “Semaglutide sets the bar for a new generation of more effective weight loss drugs.”
The multi-site study evaluated the efficacy and safety of a weekly injection of 2.4 mg semaglutide along with individual lifestyle counseling sessions.
Assuming an average basis weight of 230 lbs. With a body mass index of 38 kg / m2, the participants’ mean weight loss was 14.9% (34 lbs.) Compared to 2.4% (5 lbs.) In the placebo group. Compared to other weight loss drugs currently on the market that have been shown to help people lose between 6 and 11% of their body weight, semaglutide is about 1.5 to 2 times more effective.
Approximately 70% of the study participants achieved a weight loss of at least 10% of their base body weight, which is clinically relevant, Kushner said.
“Many of the health concerns we see in people struggling with their weight, such as diabetes, high blood pressure, or gastroesophageal reflux disease (GERD), tend to improve when they achieve 10% weight loss,” said Kushner.
20%About a third of the participants lost 20% or more of their weight
In addition, a third of the study participants treated with semaglutide lost at least 20% of their basic weight. This is a common reduction for many patients who have had bariatric surgery in the one to three years after their procedure.
“It is the very first time that we have a drug that even approaches the weight loss that people get with bariatric surgery,” said Kushner. Bariatric surgery is still more effective than this drug, but the operation carries additional risks.
After the intervention, participants treated with semaglutide reported improved physical function, e.g. B. Walking faster and climbing stairs with less pain. In addition, they made greater improvements in blood pressure, blood lipids, and blood sugar control.
The drug is intended for long-term use, said Kushner.
How the study worked
A total of 1961 overweight or obese adults took part in the 68-week study from autumn 2019 to spring 2020 at 129 locations in 16 countries. A total of 94.3% of the participants completed the study.
Participants took semaglutide by subcutaneous injection once a week (similar to someone taking insulin for diabetes) and received individual counseling from registered dietitians every four weeks to keep them on the reduced calorie diet and increased physical activity. These personal or telephone consultations gave the participants guidance, behavioral strategies and motivation. . In addition, the participants received incentives such as kettle balls or food scales to mark progress and milestones.
Side effects of the drug included mild to moderate nausea and diarrhea, which were temporary and generally resolved without permanently stopping the study, Kushner said.
Semaglutide is currently on the market to help treat diabetes, but it is only approved for a lower dose. The U.S. Food and Drug Administration is currently reviewing use at a higher dose by specifically contributing to helping individuals lose weight.
Dr. Kushner was the corresponding author for the Semaglutide Treatment in People with Obesity (STEP) 1 study group.
John Wilding, Professor of Cardiovascular and Metabolic Medicine at the Institute for Aging and Chronic Diseases, University of Liverpool, is the study’s lead author. Thomas A. Wadden, PhD, the Albert J. Stunkard Professor of Psychology in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania, and Dr. Dr. Ildiko Lingvay, professor of internal medicine at UT Southwestern Medical Center, were also co-co-professor authors.
The study was funded by Novo Nordisk, makers of Rybelsus and Ozempic (semaglutide, used to treat diabetes). Dr. Kushner has received advisory fees from Novo Nordisk.